135 related articles for article (PubMed ID: 27034797)
1. Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma.
Jakharia A; Borkakoty B; Singh S
J Gastrointest Oncol; 2016 Apr; 7(2):278-83. PubMed ID: 27034797
[TBL] [Abstract][Full Text] [Related]
2. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.
Esposito I; Kayed H; Keleg S; Giese T; Sage EH; Schirmacher P; Friess H; Kleeff J
Neoplasia; 2007 Jan; 9(1):8-17. PubMed ID: 17325739
[TBL] [Abstract][Full Text] [Related]
4. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers.
Isler SG; Schenk S; Bendik I; Schraml P; Novotna H; Moch H; Sauter G; Ludwig CU
Int J Oncol; 2001 Mar; 18(3):521-6. PubMed ID: 11179481
[TBL] [Abstract][Full Text] [Related]
5. Associations of tumor suppressor SPARCL1 with cancer progression and prognosis.
Li T; Liu X; Yang A; Fu W; Yin F; Zeng X
Oncol Lett; 2017 Sep; 14(3):2603-2610. PubMed ID: 28927026
[TBL] [Abstract][Full Text] [Related]
6. SPARCL1 a novel player in cancer biology.
Gagliardi F; Narayanan A; Mortini P
Crit Rev Oncol Hematol; 2017 Jan; 109():63-68. PubMed ID: 28010899
[TBL] [Abstract][Full Text] [Related]
7. Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma.
Luo HL; Chiang PH; Huang CC; Su YL; Sung MT; Tsai EM; Lin CS; Chiang PH
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987093
[TBL] [Abstract][Full Text] [Related]
8. Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins.
Brekken RA; Sullivan MM; Workman G; Bradshaw AD; Carbon J; Siadak A; Murri C; Framson PE; Sage EH
J Histochem Cytochem; 2004 Jun; 52(6):735-48. PubMed ID: 15150282
[TBL] [Abstract][Full Text] [Related]
9. [Expression and prognosis effect of methylation-regulated SLIT3 and SPARCL1 genes in smoking-related lung adenocarcinoma].
Wang J; Yu XF; Ouyang N; Zhao SY; Guan XF; Yao HP; Chen R; Chen T; Li JX
Zhonghua Yi Xue Za Zhi; 2019 May; 99(20):1553-1557. PubMed ID: 31154721
[No Abstract] [Full Text] [Related]
10. Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.
He K; Li C; Yuan H; Jiang K; Deng G
Pathol Oncol Res; 2022; 28():1610687. PubMed ID: 36483097
[No Abstract] [Full Text] [Related]
11. Astrocyte matricellular proteins that control excitatory synaptogenesis are regulated by inflammatory cytokines and correlate with paralysis severity during experimental autoimmune encephalomyelitis.
Blakely PK; Hussain S; Carlin LE; Irani DN
Front Neurosci; 2015; 9():344. PubMed ID: 26500475
[TBL] [Abstract][Full Text] [Related]
12. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.
Shen C; Yin Y; Chen H; Wang R; Yin X; Cai Z; Zhang B; Chen Z; Zhou Z
BMC Gastroenterol; 2018 Jul; 18(1):105. PubMed ID: 29973149
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of SPARCL1 in patients with colorectal cancer.
Han W; Cao F; Ding W; Gao XJ; Chen F; Hu YW; Ding HZ
Oncol Lett; 2018 Feb; 15(2):1429-1434. PubMed ID: 29434834
[TBL] [Abstract][Full Text] [Related]
14. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.
Hurley PJ; Marchionni L; Simons BW; Ross AE; Peskoe SB; Miller RM; Erho N; Vergara IA; Ghadessi M; Huang Z; Gurel B; Park BH; Davicioni E; Jenkins RB; Platz EA; Berman DM; Schaeffer EM
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14977-82. PubMed ID: 22927397
[TBL] [Abstract][Full Text] [Related]
15. Modulation of SPARC/Hevin Proteins in Alzheimer's Disease Brain Injury.
Strunz M; Jarrell JT; Cohen DS; Rosin ER; Vanderburg CR; Huang X
J Alzheimers Dis; 2019; 68(2):695-710. PubMed ID: 30883351
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.
Cao F; Wang K; Zhu R; Hu YW; Fang WZ; Ding HZ
Asian Pac J Cancer Prev; 2013; 14(1):195-200. PubMed ID: 23534723
[TBL] [Abstract][Full Text] [Related]
17. MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1.
Gong YB; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2366-2373. PubMed ID: 30964161
[TBL] [Abstract][Full Text] [Related]
18. SPARCL1 expression increases with preoperative radiation therapy and predicts better survival in rectal cancer patients.
Kotti A; Holmqvist A; Albertsson M; Sun XF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1196-202. PubMed ID: 24661672
[TBL] [Abstract][Full Text] [Related]
19. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.
Ma Y; Xu Y; Li L
Exp Ther Med; 2018 Oct; 16(4):3195-3201. PubMed ID: 30233672
[TBL] [Abstract][Full Text] [Related]
20. SPARCL1 Influences Bovine Skeletal Muscle-Derived Satellite Cell Migration and Differentiation through an ITGB1-Mediated Signaling Pathway.
Wang Y; Liu S; Yan Y; Li S; Tong H
Animals (Basel); 2020 Aug; 10(8):. PubMed ID: 32781616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
